Improving doxorubicin treatment in ovarian cancer

**公开描述：**基因测试用于指导许多癌症的治疗，但每种癌症需要不同的测试。英国国家医疗服务体系目前正在将许多基因检测合并为一个涵盖500个基因的单一检测。这是向前迈出的重要一步，并提供了将测试扩展到新药反应预测和为患者提供更多治疗选择的机会。然而，并不是所有的癌症都能从覆盖500个基因的测试中立即受益。在卵巢癌中，目前只有两种基因用于帮助选择一种药物治疗-奥拉帕尼。使用新技术，Tailor Bio开发了一种新的测试，可以识别对阿霉素（另一种常用的治疗卵巢癌的药物）没有反应的患者。在确定了这些病人之后，临床医生可以给其他类型的药物，可能有更大的好处。在这个项目中，我们将把Tailor Bio的新测试与NHS目前使用的大型500个基因测试结合起来。作为该项目的一部分，我们将*调整软件以组合测试*计划联合测试的临床试验*调查联合测试的成本效益。该项目的成功将为英国每年约4000人提供更好的治疗选择。

**Public description:** Genetic tests are used to guide the treatment of many cancers, but each type of cancer requires a different test. The NHS is currently combining many genetic tests into a single test covering 500 genes. This is a major step forward and offers the opportunity to extend the testing to new drug response predictions and provide more treatment options for patients.However, not all cancers will immediately benefit from a test covering 500 genes. In ovarian cancer there are currently only 2 genes which are used to help select 1 type of drug treatment - olaparib.Using novel techniques, Tailor Bio has developed a new test that identifies patients who will not respond to doxorubicin, another drug commonly used to treat ovarian cancer. After identifying these patients, clinicians can then give other types of drugs which might have greater benefit.In this project we will combine Tailor Bio's novel test with the large 500-gene tests currently being used by the NHS. As part of this project we will* Adapt software to combine the tests* Plan a clinical trial of the combined test* Investigate the cost effectiveness of the combined testSuccess in this project will allow better treatment selection for approximately 4000 people in the UK annually.